11.40
0.08 (0.71%)
| Previous Close | 11.32 |
| Open | 11.34 |
| Volume | 142,522 |
| Avg. Volume (3M) | 1,121,534 |
| Market Cap | 1,107,201,920 |
| Price / Book | 3.01 |
| 52 Weeks Range | |
| Earnings Date | 11 Nov 2025 |
| Diluted EPS (TTM) | -1.88 |
| Total Debt/Equity (MRQ) | 3.97% |
| Current Ratio (MRQ) | 12.00 |
| Operating Cash Flow (TTM) | -115.01 M |
| Levered Free Cash Flow (TTM) | -68.48 M |
| Return on Assets (TTM) | -30.87% |
| Return on Equity (TTM) | -48.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Oric Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -3.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.30 |
|
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 7.93% |
| % Held by Institutions | 102.70% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nextech Invest, Ltd. | 30 Jun 2025 | 7,162,637 |
| Nextech Invest Ltd. | 31 Dec 2024 | 5,285,714 |
| Sr One Capital Management, Lp | 30 Jun 2025 | 4,514,929 |
| First Turn Management, Llc | 30 Jun 2025 | 2,009,923 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 19.00 (HC Wainwright & Co., 66.67%) | Buy |
| Median | 17.50 (53.51%) | |
| Low | 15.00 (Ladenburg Thalmann, 31.58%) | Buy |
| Average | 17.25 (51.32%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 10.27 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 04 Sep 2025 | 18.00 (57.89%) | Buy | 10.77 |
| 13 Aug 2025 | 18.00 (57.89%) | Buy | 9.83 | |
| HC Wainwright & Co. | 14 Aug 2025 | 19.00 (66.67%) | Buy | 9.93 |
| JP Morgan | 14 Aug 2025 | 17.00 (49.12%) | Buy | 9.93 |
| Ladenburg Thalmann | 08 Jul 2025 | 15.00 (31.58%) | Buy | 10.43 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHACKO JACOB | - | 10.82 | -125,000 | -1,352,500 |
| Aggregate Net Quantity | -125,000 | |||
| Aggregate Net Value ($) | -1,352,500 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 10.82 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CHACKO JACOB | Officer | 22 Sep 2025 | Automatic sell (-) | 125,000 | 10.82 | 1,352,500 |
| Date | Type | Details |
|---|---|---|
| 27 Aug 2025 | Announcement | ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 18 Aug 2025 | Announcement | ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer |
| 12 Aug 2025 | Announcement | ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |